• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服伊曲康唑治疗足部真菌性马杜拉足的临床治愈情况

Clinical cure of fungal madura foot with oral itraconazole.

作者信息

Paugam A, Tourte-Schaefer C, Keïta A, Chemla N, Chevrot A

机构信息

Department of Parasitology-Mycology, Pneumology, and Radiology, CHU Cochin-Port-Royal, Paris, France.

出版信息

Cutis. 1997 Oct;60(4):191-3.

PMID:9347233
Abstract

We report the case of a 26-year-old Malian patient who presented with mycetoma of the foot and frank bone involvement caused by Madurella mycetomatis. Long-term itraconazole therapy was clinically effective and well tolerated.

摘要

我们报告了一例26岁的马里患者,该患者足部患有足菌肿且明确有马杜拉放线菌引起的骨受累。长期伊曲康唑治疗在临床上有效且耐受性良好。

相似文献

1
Clinical cure of fungal madura foot with oral itraconazole.口服伊曲康唑治疗足部真菌性马杜拉足的临床治愈情况
Cutis. 1997 Oct;60(4):191-3.
2
Eumycotic mycetoma caused by Madurella mycetomatis successfully treated with antifungals, surgery, and topical negative pressure therapy.由马杜拉足肿菌引起的真菌性足菌肿经抗真菌药物、手术及局部负压治疗成功治愈。
Int J Dermatol. 2009 Apr;48(4):401-3. doi: 10.1111/j.1365-4632.2009.03967.x.
3
[Mycetoma].[足菌肿]
Ann Dermatol Venereol. 2008 Aug-Sep;135(8-9):626-8. doi: 10.1016/j.annder.2008.03.007. Epub 2008 May 27.
4
Madurella mycetomatis mycetoma treated successfully with oral posaconazole.用口服泊沙康唑成功治疗马杜拉足分支菌所致足菌肿
J Chemother. 2011 Aug;23(4):243-4.
5
Paecilomyces lilacinus eumycetoma.淡紫拟青霉性足菌肿
Int J Dermatol. 2009 Aug;48(8):858-61. doi: 10.1111/j.1365-4632.2008.04047.x.
6
The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.伊曲康唑治疗足放线菌属真菌病引起的真菌性足菌肿患者的安全性和疗效。
Trans R Soc Trop Med Hyg. 2011 Mar;105(3):127-32. doi: 10.1016/j.trstmh.2010.11.008. Epub 2011 Jan 17.
7
Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin.病例报告:口服泊沙康唑和环丙沙星对足分支菌病的非侵入性治疗
Am J Trop Med Hyg. 2014 Dec;91(6):1259-62. doi: 10.4269/ajtmh.14-0335. Epub 2014 Oct 27.
8
[Painful swelling of the foot of a 16-year-old African. Eumycetoma (Madura foot)].[一名16岁非洲青少年足部疼痛性肿胀。足菌肿(马杜拉足)]
Hautarzt. 2001 Jul;52(7):672-6. doi: 10.1007/s001050170114.
9
Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.马杜拉足分支菌中的黑色素生物合成及其对伊曲康唑和酮康唑敏感性的影响。
Microbes Infect. 2007 Jul;9(9):1114-23. doi: 10.1016/j.micinf.2007.05.015. Epub 2007 May 18.
10
Madurella mycetomatis-Induced Massive Shoulder Joint Destruction: A Management Challenge.马杜拉足分支菌引起的肩关节严重破坏:治疗挑战
PLoS Negl Trop Dis. 2016 Aug 4;10(8):e0004849. doi: 10.1371/journal.pntd.0004849. eCollection 2016 Aug.

引用本文的文献

1
Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.重新利用美国食品药品监督管理局(FDA)批准的药物治疗足菌肿:CYP51抑制剂的同源建模与计算筛选
Int J Mol Sci. 2025 Jan 1;26(1):315. doi: 10.3390/ijms26010315.
2
Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.引起足菌肿的马杜拉分支菌的医学治疗:挑战与前景。
PLoS Negl Trop Dis. 2020 Aug 27;14(8):e0008307. doi: 10.1371/journal.pntd.0008307. eCollection 2020 Aug.
3
ACTINOMYCETOMA OF HAND AND FOOT.
手足放线菌性足菌肿
Med J Armed Forces India. 2000 Jul;56(3):252-254. doi: 10.1016/S0377-1237(17)30184-3. Epub 2017 Jun 10.
4
Mycetoma medical therapy.足菌肿的医学治疗。
PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3218. doi: 10.1371/journal.pntd.0003218. eCollection 2014 Oct.
5
Eumycetoma of the hand caused by Leptosphaeria tompkinsii and refractory to medical therapy with voriconazole.由托金斯莱氏枝孢霉引起的手部外源性真菌病,对伏立康唑药物治疗有抗药性。
Mycopathologia. 2011 Oct;172(4):311-5. doi: 10.1007/s11046-011-9432-8. Epub 2011 May 13.
6
Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.采用Sensititre系统,与基于活力的2,3-双(2-甲氧基-4-硝基-5-磺基苯基)-5-[(苯基氨基)羰基]-2H-氢氧化四唑(XTT)检测法及改良的美国国立临床实验室标准化委员会(NCCLS)方法相比较,对马杜拉足分支菌的体外药敏性进行检测。
Antimicrob Agents Chemother. 2005 Apr;49(4):1364-8. doi: 10.1128/AAC.49.4.1364-1368.2005.